YOLFTbeta
68

Shouyao Holdings (Beijing) Co. Ltd. A

688197 · SHG · Healthcare / Biotechnology

32.90CNY-1.10 (-3.24%)

Price History

Full chart

Market Stats

Previous Close34.00
Open34.03
Day Range32.55 – 34.23
52-Week Range29.71 – 46.25
Volume1.44M
Market Cap5.61B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.58
Dividend Yield0.00%
Beta0.67
50-Day Avg35.02
200-Day Avg37.21

About

Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Wenjun Li
  • Employees184
  • HeadquartersBuilding 20, Beijing, China, 100195, China
  • Websitehttps://www.shouyaoholding.com

Leadership

  • Mr. Wenjun LiChairman of the Board & GM · b. 1967
  • Ms. Yajie WangAccounting Supervisor & Chief Financial Officer · b. 1970
  • Mr. Xin He XuSenior Manager of Pharmacy Department & Director · b. 1974
  • Ms. Ying Li ZhangBoard Secretary · b. 1984
  • Mr. Yan ZhuDeputy General Manager · b. 1981
  • Mr. Xi Jie LiuDeputy General Manager · b. 1976
  • Mr. Li Min YangDeputy General Manager · b. 1976
  • Ms. Ying Hui SunDeputy General Manager · b. 1980
  • Ms. An Na WangDirector of Clinical Medicine · b. 1981
  • Ms. Jing Can WangDirector of Registration · b. 1983

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue11.55M7.02M13.03M1.83M5.23M3.94M8.67M
Growth (%)--39.22%+85.67%-85.98%+186.18%-24.61%+119.88%
Cost of Revenue1.40M4.13K8.81K11.48K111.31K41.15K266.10K
Gross Profit10.15M7.01M13.02M1.82M5.12M3.90M8.40M
Gross Margin87.89%99.94%99.93%99.37%97.87%98.96%96.93%
Operating Expense48.56M343.08M159.81M197.21M216.76M229.76M154.83M
Operating Income-38.41M-336.07M-146.79M-195.39M-211.64M-225.86M-146.43M
Operating Margin-332.62%-4787.93%-1126.30%-10693.56%-4047.36%-5729.60%-1689.36%
EBITDA-34.75M-328.81M-139.39M-167.14M-178.29M-205.04M-121.57M
EBITDA Margin-300.92%-4684.44%-1069.52%-9147.39%-3409.47%-5201.38%-1402.53%
Net Income-39.61M-330.12M-144.92M-173.82M-185.57M-211.94M-128.83M
Net Income Margin-343.00%-4703.18%-1112.00%-9512.74%-3548.79%-5376.40%-1486.39%
R&D43.91M85.03M156.84M199.44M202.66M212.68M196.70M
R&D as % of Total Revenue380.25%1211.45%1203.46%10914.97%3875.51%5395.23%2269.38%
Interest Expense466.68K397.93K138.15K341.00K158.05K184.17K133.14K
Interest Expense % of Total Revenue4.04%5.67%1.06%18.66%3.02%4.67%1.54%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets218.89M182.13M58.18M1.30B1.11B922.23M791.23M
Total Liabilities44.33M35.71M56.67M92.73M91.16M113.21M111.05M
Total Equity173.84M146.42M1.50M1.21B1.02B809.01M680.18M
Cash142.08M142.35M24.45M1.19B530.34M22.73M17.59M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-84.66M-93.17M-104.04M-129.48M-179.57M-196.77M-157.83M
Capital Expenditure1.14M3.36M7.35M20.70M3.83M8.57M3.20M
Free Cash Flow-85.80M-96.53M-111.38M-150.19M-183.40M-205.33M-161.03M
Dividends Paid---128.10K---
FCF to OCF101.35%103.61%107.06%115.99%102.13%104.35%102.03%
Dividend Paid to FCF----0.09%---

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----
EPS Actual-0.34-0.22-0.24-0.37-0.32
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap5.61B
Enterprise Value5.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales161.73
Price / Book9.48
EPS-0.58
Book Value4.16
Revenue (TTM)34.67M
Gross Profit (TTM)34.40M
EBITDA-158.60M
Profit Margin-246.69%
Operating Margin-464.35%
Return on Equity-12.92%
Return on Assets-13.02%
Shares Outstanding148.72M
Shares Float55.50M
Beta0.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%